Skip to main content
Fig. 2 | Respiratory Research

Fig. 2

From: Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial

Fig. 2

Change from baseline in (a) trough FEV1 and (b) TDI total scores with IND/GLY versus comparators at Week 12 (ITT population). *P < 0.0001. #Patients had an mMRC score ≥ 2. Data are least squares means (95% CI). ∆, treatment difference; CI, confidence interval; FEV1, forced expiratory volume in 1 s; IND/GLY, indacaterol/glycopyrronium; ITT, intention-to-treat; LABA + ICS, long-acting β2-agonist + inhaled corticosteroid; LAMA, long-acting muscarinic antagonist; mMRC, modified Medical Research Council; TDI, transition dyspnoea index

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us